prostate cancer
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved Nubeqa for metastatic castration-sensitive prostate cancer.
JUNE 6, 2025
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for Pluvicto to include adults with PSMA-positive metastatic castration-resistant ...
APRIL 2, 2025
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia and Xgeva.
MARCH 7, 2024
FDA Approves Xtandi for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
The FDA approved enzalutamide (Xtandi, Astellas Pharma) for nonmetastatic castration-sensitive prostate cancer ...
NOVEMBER 21, 2023
The Unequal Promise of Prostate Cancer Therapy
Triplet therapies that combine androgen deprivation therapy, infusion chemotherapy and oral hormones may extend the ...
AUGUST 7, 2023
Adding Talazoparib to Enzalutamide in mCRPC Improves Outcomes
In patients with metastatic, castration-resistant prostate cancer, adding the PARP inhibitor talazoparib (Talzenna, ...
MARCH 17, 2023
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
Continuing Enzalutamide After Progression and Adding Docetaxel Improved PFS in mCRPC, Study Shows
Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended ...
MARCH 25, 2022
Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer
The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for ...
MARCH 25, 2022
FDA Approves Orgovyx to Treat Prostate Cancer
The FDA approved relugolix (Orgovyx, Myovant Sciences), the first oral androgen deprivation therapy for adults with ...
JANUARY 7, 2021
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 20, 2020
